SUBSCRIBE
SUBSCRIBE

AstraZeneca

NEWS
Business
AstraZeneca Inks R&D Deal With Ramaswamy’s Roivant for Hush-Hush Indication
Vivek Ramaswamy’s parent company, Roivant Sciences, inked a development deal with Astra.
October 19, 2017
 · 
3 min read
 · 
Mark Terry
Sotera Employees Misappropriated Masimo Trade Secr
Policy
Big Pharma Allegedly Funded Anti-U.S. Militia in Iraq
The lawsuit was filed on behalf of members of the American military who were injured or killed by attacks between 2005 and 2009
October 18, 2017
 · 
1 min read
Why AstraZeneca PLC CEO Took a Job His Friends Called a Suicide Mission
Business
Why AstraZeneca PLC CEO Took a Job His Friends Called a Suicide Mission
October 11, 2017
 · 
3 min read
Business
AstraZeneca PLC May Move Some Manufacturing, R&D Out Of The UK Due To Brexit
October 4, 2017
 · 
1 min read
Deals
Why AstraZeneca PLC’s ‘Big Pipeline’ Makes It A Possible Take-Out Candidate
September 22, 2017
 · 
1 min read
Massachusetts' Biostage Slashes 71% of Staff, Evaluating Strategic Alternatives
Business
Massachusetts’ Flexion Terminates R&D Deal With AstraZeneca PLC
September 15, 2017
 · 
2 min read
AstraZeneca PLC Offloads Remaining Anesthetics Portfolio in $766 Million Deal
Deals
AstraZeneca PLC Offloads Remaining Anesthetics Portfolio in $766 Million Deal
September 14, 2017
 · 
3 min read
AstraZeneca PLC: Is It Investable After Imfinzi Failure?
September 8, 2017
 · 
1 min read
AstraZeneca PLC Offloads Remaining Anesthetics Portfolio in $766 Million Deal
Drug Development
Investors Wait with Bated Breath for AstraZeneca PLC’s Cancer Trial Data Next Week
September 1, 2017
 · 
3 min read
Load More
AWARDS
  • 2022 Best Places to Work
  • 2024 Best Places to Work
JOBS
IN THE PRESS
Press Releases
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy
June 26, 2026
 · 
10 min read
Press Releases
AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer
June 18, 2026
 · 
7 min read
Press Releases
AstraZeneca Joins ZERO Prostate Cancer’s Historic ‘Blitz the Barriers’ Initiative as a Founding Partner
June 15, 2026
 · 
3 min read
Press Releases
TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer
June 14, 2026
 · 
19 min read
Press Releases
AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
June 8, 2026
 · 
7 min read
Press Releases
Leica Biosystems Announces Expansion of Collaboration to Scale Precision Medicine and Develop AI-Powered Diagnostics
June 3, 2026
 · 
4 min read
Press Releases
AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Clinical Milestones
June 1, 2026
 · 
7 min read
Press Releases
IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
May 29, 2026
 · 
19 min read
Press Releases
DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates
May 24, 2026
 · 
19 min read
Press Releases
Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
May 24, 2026
 · 
19 min read
Load More